BCL2 and neoplasm: The addition of venetoclax, a Bcl-2 specific inhibitor, did not show sensitization of the tumor cells to olaparib, but the addition of navitoclax, a dual inhibitor of Bcl-2 and Bcl-xL, induced a sensitization of the tumor cells to the PARP inhibitor, with a marked loss of cell viability, even with low doses of olaparib, in two different cell lines, one chemoresistant and other chemosensitive.